non-Hodgkin lymphoma | sciencenewsnet.in

CD19 CAR NK-cell therapy achieves 73% response rate in patients with leukemia and lymphoma

February 5, 2020 sarah Jonas Cell Therapy, CLL, Immunotherapy, Leukemia, Lymphoma, MD Anderson Cancer Center, New England Journal Of Medicine, non-Hodgkin lymphoma

According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK)-cell therapy targeting CD19 resulted in clinical responses in a majority of patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL), with no major toxicities observed.

Research Results

Study shows protein inhibitor as potential treatment approach for common mutations found in non-Hodgkin lymphomas

January 8, 2020 sarah Jonas 0 Comments Cancer, Follicular Lymphoma, Immunotherapy, Lymphoma, non-Hodgkin lymphoma

Study shows protein inhibitor as potential treatment approach for common mutations found in non-Hodgkin lymphomas. Findings may create immunotherapy options for lymphomas caused by CREBBP mutations.

Research Results

Retrospective Analysis Identifies Need for Better Classification of Rare Lymphoma

December 4, 2019 sarah Jonas 0 Comments Lymphoma, New Jersey, non-Hodgkin lymphoma, Rutgers University

In what is believed to be one of the largest studies of a rare disorder known as primary cutaneous gamma delta T-cell lymphoma, Rutgers Cancer Institute
investigators and other collaborators examined characteristics, treatment patterns and outcomes and determined accurate diagnosis of the disease requires ongoing analysis.

Research Results

Calcium Signaling Identified as Exploitable Target in Addressing Drug Resistance to Non-Hodgkin Lymphoma Treatment

December 2, 2019 sarah Jonas 0 Comments Antibody Therapy, ASH annual meeting, Drug Resistance, New Jersey, non-Hodgkin lymphoma, Rutgers University

Gene expression profiling and other analyses conducted by Rutgers Cancer Institute of New Jersey researchers and colleagues examining drug resistance to a common antibody therapy for non-Hodgkin lymphoma have identified calcium signaling as a novel and exploitable target in overcoming this treatment obstacle. Results are being presented at the American Society of Hematology Annual Meeting.